This penny share could be one of the best stocks to buy in September

Next month could prove to be very interesting for holders of this penny share. Paul Summers looks at whether now’s the perfect time for him to buy in.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Penny shares have the potential to dramatically increase the wealth of investors in a way FTSE 100 giants can’t, at least over a short period of time. Today, I’m going to look at what could turn out to be one of the best stocks to buy from this part of the market in September. 

The best penny share to buy now?

The company in question is medical imaging technology firm Polarean Imaging (LSE: POLX). Its non-invasive drug-device combination product helps clinicians diagnose lung disease. It also allows them to identify the best treatment for the patient and then regularly check in to see whether said treatment is working or not. As it sounds, this could be a big deal for pulmonary medicine.

Following two successful Phase III clinical trials, Polarean’s Xenon gas MRI now needs to be approved by the US Food and Drug Administration (FDA). Importantly, a response on this is expected by 5 October, hence why this penny share’s grabbing my attention now. 

So it’s looking positive then?

Based on recent activity, Polarean seems to think so. In anticipation of good news, the company has already taken on sales and marketing staff for when the product is officially commercialised. This should allow it to hit the ground running if/when it gets the green light. The potential demand could be huge. 

Polarean certainly isn’t short of backers either. It raised £27m earlier in the year from several UK and US institutional investors in an oversubscribed funding round. Specialist fund manager Amarti Global, for example, holds a little over 12% of the company which now commands a market capitalisation of £180m. 

All this makes POLX potentially attractive, in my opinion. So what things do I need to be aware of?

No sure thing

Well, one thing to highlight is the superb performance of this penny share to date. It’s more than doubled in value over the last 12 months. Since coming to the market in March 2018, the stock’s up over 400%.

I doubt early holders will be complaining. Then again, it’s worth asking how much of Polarean’s potential is now priced in. After all, it barely makes any revenue and will still have zero profit following approval. Adoption by hospitals will take time. Having come so far in so little time, one might wonder whether a ‘thumbs up’ from the FDA might be actually greeted with a shrug of the shoulders by the market. The share price may even fall as profits are banked by short-term traders.

Of course, there’s always the potential that Polarean might not gain clearance from the FDA, due to safety concerns. Such a scenario might be unthinkable to those already holding. However, I’ve been burned on such decisions in the past. I’m wary of assuming anything’s in the bag.   

Regardless of which direction POLX stock may go next month, I also need to remember that the company’s small-cap status (and therefore relative illiquidity) may exacerbate this move. 

Small position

In sum, POLX strikes me as a potentially exciting investment to make in September (even though this alternative stock remains my favourite penny share). That said, its almost binary nature makes it one that I most definitely wouldn’t bet all my capital on.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Photo of a man going through financial problems
Investing Articles

Is a stock market crash coming? And what should I do now?

Global investors are panicking about a new US stock market crash in the days or weeks ahead. Here's how I'm…

Read more »

Investing Articles

FTSE shares: a brilliant opportunity for investors to get rich?

With valuations in the US looking full, Paul Summers thinks there's a good chance that FTSE stocks might become more…

Read more »

Growth Shares

2 FTSE 100 stocks that could outperform the index in 2025

Jon Smith flags up a couple of FTSE 100 stocks that have strong momentum right now and have beaten the…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

1 stock market mistake to avoid in 2025

This Fool has been battling bouts of of FOMO recently, as one of his growth shares enjoys a big bull…

Read more »

Investing Articles

2 no-brainer buys for my Stocks and Shares ISA in 2025

Harvey Jones picks out a couple of thriving FTSE 100 companies that he's keen to add to his Stocks and…

Read more »

Number three written on white chat bubble on blue background
Investing For Beginners

3 investing mistakes to avoid when buying UK shares for 2025

Jon Smith flags up several points for investors to note when it comes to thinking about which UK shares to…

Read more »

Investing Articles

Will the rocketing Scottish Mortgage share price crash back to earth in 2025?

The recent surge in the Scottish Mortgage share price caught Harvey Jones by surprise. He was on the brink of…

Read more »

Investing Articles

2 cheap shares I’ll consider buying for my ISA in 2025

Harvey Jones will be on the hunt for cheap shares for his ISA in 2025 and these two unsung FTSE…

Read more »